Literature DB >> 16647594

Spinal cord stimulation for critical leg ischemia: a review of effectiveness and optimal patient selection.

Dirk Th Ubbink1, Hester Vermeulen.   

Abstract

Patients suffering from inoperable critical leg ischemia (CLI) ultimately face a major amputation. Spinal cord stimulation (SCS) has been introduced as a possible treatment option. This paper presents the best available evidence from a systematic review on the effectiveness of SCS in these patients and discusses the indications for SCS therapy. A meta-analysis of six controlled trials, including 444 patients, showed 11% (95% confidence interval: -0.02 to -0.20) lower amputation rate after 12 months compared to those treated with optimum medical treatment. In addition, SCS patients required significantly fewer analgesics and showed a significant clinical improvement. These positive effects have to be weighed against the higher costs and (generally minor) complications of SCS. TcpO(2) measurements were found to be useful in selecting the most respondent patients, yielding a 12-month limb salvage up to 83%. Hence, SCS should be considered as a possible treatment option in patients with CLI, particularly if their foot TcpO(2) is between 10 and 30 mmHg.

Entities:  

Mesh:

Year:  2006        PMID: 16647594     DOI: 10.1016/j.jpainsymman.2005.12.013

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  13 in total

Review 1.  [Epidural spinal cord stimulation for therapy of chronic pain. Summary of the S3 guidelines].

Authors:  V Tronnier; R Baron; F Birklein; S Eckert; H Harke; D Horstkotte; P Hügler; M Hüppe; B Kniesel; C Maier; G Schütze; R Thoma; R D Treede; V Vadokas
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

Review 2.  Spinal cord stimulation for chronic limb ischemia.

Authors:  Joseph J Naoum; Elias J Arbid
Journal:  Methodist Debakey Cardiovasc J       Date:  2013-04

3.  Spinal cord stimulation to achieve wound healing in a primary lower limb critical ischaemia referral centre.

Authors:  Giovanni De Caridi; Mafalda Massara; Antonio David; Massimiliano Giardina; Michele La Spada; Francesco Stilo; Francesco Spinelli; Raffaele Grande; Lucia Butrico; Stefano de Franciscis; Raffaele Serra
Journal:  Int Wound J       Date:  2014-04-08       Impact factor: 3.315

4.  Management of infrapopliteal peripheral arterial occlusive disease.

Authors:  Warren J Gasper; Sara J Runge; Christopher D Owens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-04

5.  The effectiveness and cost-effectiveness of spinal cord stimulation for refractory angina (RASCAL study): study protocol for a pilot randomized controlled trial.

Authors:  Sam Eldabe; John Raphael; Simon Thomson; Andrea Manca; Mark de Belder; Rajesh Aggarwal; Matthew Banks; Morag Brookes; Susan Merotra; Rashidat Adeniba; Ed Davies; Rod S Taylor
Journal:  Trials       Date:  2013-02-22       Impact factor: 2.279

Review 6.  Cervical Spinal Cord Stimulation for Trigeminal Neuralgia: a Narrative Review.

Authors:  Mayank Gupta; Ahish Chitneni; Joe Ghorayeb; Brendan Schnetzer; Malvina Klusek
Journal:  Curr Pain Headache Rep       Date:  2022-06-18

7.  [Therapy of chronic ischemic pain in peripheral arterial disease. A survey among physicians].

Authors:  L J Rüger; D Irnich; S Grasmueller; P M Lang
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

Review 8.  Spinal cord stimulation for patients with inoperable chronic critical leg ischemia.

Authors:  Xiao-Pei Chen; Wei-Min Fu; Wei Gu
Journal:  World J Emerg Med       Date:  2011

9.  Spinal cord stimulation for refractory angina pectoris -a case report-.

Authors:  Seong Heon Lee; Hye Jin Jeong; Sin Ho Jeong; Hyung Gon Lee; Jeong Il Choi; Myung Ha Yoon; Woong Mo Kim
Journal:  Korean J Pain       Date:  2012-04-04

10.  Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials.

Authors:  Rod S Taylor; Jessica De Vries; Eric Buchser; Mike J L Dejongste
Journal:  BMC Cardiovasc Disord       Date:  2009-03-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.